Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders....
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of NERV is 4.6 and suggests 40% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr
Buy
Sell